Vectura Group – a listed, UK-based developer of inhaled drug delivery devices – has approved a take-private offer from Carlyle valuing the business at £958m.
French sponsor seeks to attract state-backed LPs for new strategy targeting ESG-focused startups
Director appointments include Rutland Partners' Matt Hamilton-Allen, who joins the investment team
New vehicle exceeded target by more than USD 300m; aims for up to 20% exposure to European debt
New vehicle will invest at the crossover of health care, life sciences and tech with EUR 5m-50m tickets